updat model post recent event ep estim increas modestli
near term lower modestli longer term price target rais higher n-t estim
stock compel given growth prospect manag abil deliv
pe multipl march meet import mileston get littl credit
pipelin rival recogn innov
benefit number recent event reflect model
better-than-expect result stand-alone guidanc appear
higher previous forecast although tough certain given model reflect
acquisit solid number last-publish model assum
acquisit close januari assum close march
gate item close ftc approv follow irish high court approv
administr process take roughli week follow ftc approv
provid combin entiti guidanc upon closur acquisit
rais ep estim
thereaft estim
trim year new ep estim impli
ep growth versu project declin
ep target price rais vs previous base higher ep
estim
reflect later assum close transact sale estim
lower thereaft sale estim chang modest
rang year new sale
estim impli sale growth versu
project sale growth
forecast oper margin increas last
publish forecast thereaft oper margin forecast
roughli unchang sinc januari puls report
host meet march headquart effort provid
visibl abbv effort provid opportun engag senior member
 organ think import event
pipelin candid compani track univers roughli equal compani
well known innov capabl sni yet get littl
recognit aspect compani
pleas see page report import disclosur
provid long-term stand-alone guidanc expect humira
appear solid foot forese futur competit
posit hepat segment oncolog compani promis
new product line-up pipelin acquisit allergan outperform
cover ken cacciator increas visibl particularli humira patent
expir stock look attract valu versu group overal
attribut argu purchas share
rinvoq roll-out ra
skyrizi /eu uptak psoriasi
new indic competit
landscap venclexta/imbruvica
humira sale trend eu
humira sale
humira biosimilar eros less
especi oncolog immunolog
 bolster long-term visibl
humira erod quickli
expect eu and/or launch
oncolog immunolog product
global biopharmaceut compani product use treat rheumatoid
arthriti psoriasi crohn ulcer coliti hcv hematolog tumor among other
humira ra crohn domin product repres total sale
profit also pipelin compound indic phase ii
phase develop process acquir allergan expect close
compani data cowen compani
compani data cowen compani
ww foreign lc ex chang chang foreign sale report portion foreign leuprolid foreign lc ex leuprolid foreign lc ex cowen
compani data cowen compani
compani data cowen compani
compani data cowen compani
compani data cowen compani
compani data cowen compani
compani data cowen compani
compani data cowen compani
ww guidanc us growth ou ip expect hold settlement launch start humira biosimilar launch eu foreign lc ex ra pa crohn psoriasi jai uc uveiti hshumira adalimumab anti-tnf mab guidanc approach chang chang guidanc peak record sale foreign sale report includ sale total portion foreign record share ou profitsimbruvica approv hematolog cancer pcyc acq close guidanc growth acquir solvay pacrealipas enzym replac pancreat insufficiencysynthroid- guidanc flat steadi sale gener difficult formul synthroid levothyroxin overact leuprolid guidanc flat line extens support foreign lc ex leuprolid gener avail lupron still lead market mo guidanc flat foreign lc ex human mab bind f-protein divalproex acid seizur control bipolar mania ir patent expir er patent expir cowen
compani data cowen compani
 patent expir maintain share via servic foreign lc ex induct mainten gener anesthesiaultane/sevofluoran flourin isopropyl ether anesthesiaandrogel gener form launchedandrogel testosteron gel hypergonad market declin gener pressurekaletra lopinavir/low-dos ritonavir combo hiv patent exp market em aluvia combo proteas inhibitor foreign lc ex emerg market slow sale declinenorvir patent expir januari inhibit cytochrom metabol pi foreign lc ex ritonavir hiv proteas inhibitor use booster combozemplar teva gener launch foreign lc ex paricalcitol tx secondari hyperparathyroid pt ckftricor/trilipix gener launch gener launch via settlement teva/brl foreign lc ex er niacin rais hdl reduc ldlother includ gross-to-net adjust assum ceas humira patent us includ nimbex vicodin etc emerg mkt growth foreign lc ex cowen
compani data cowen compani
guidanc hcv combin glecaprevir pi pibrentasvir hcv dose tablet qd week eign lc ex all-or regimen genotyp ifn-nav hcv patientsmavyret patient without cirrhosi new treatmentviekirax exviera combin paritaprebir/r pi ombitasvir inhibitor dasabuvir non-nuc polymeras inhibitor hcv eign lc ex all-or regimen genotyp ifn-nav hcv patientsviekirax exviera ww guidanc profit roch incom line royalti estimate sale roch condit eu approv eign lc ex approv cll delet r/r cll rituxanvenclexta venetoclax select inhibitor cllorilissa- oral gnrh antagonist partial estrogen suppress guidanc endometriosi approv uterin fibrosi file partnership neurocrin eign lc ex similar lupron zoladexorilissa hold ww right elagolix gnrh antagonistsskyrizi- rizankizumab guidanc approv psoriasi ph crohn uc ph ii eign lc ex month bi bi receiv mileston royaltiesduodopa- guidanc infus directli small intestin via portabl pump like nich product refractori pd eign lc ex market solvay ousduodopa gel formul carbidopa/levodopa parkinson srinvoq- guidanc ra roll-out underway ph atop dermat ph ii axspa gca eign lc ex jak inhibitor competit profil ra crohn uc ad cowen
compani data cowen compani
 partner record profit record royalti ex-u foreign lc ex elotuzumab antibodi multipl myeloma r/r mm w/poma dexveliparib bid oral dose cross bbb foreign lc ex parp inhibitor ovarian cancer phase zinbryta foreign foreign lc ex fx zinbryta ww- daclizumab withdrawn global march foreign lc ex foreign lc ex world-wide cowen
compani data cowen compani
 bimatoprost glaucoma combin lumigan timolol cyclosporin chronic dri eye patent protect total ophthalm franchis remain key franchis new product launch key offset competit dynam moder total botox franchis nervou namenda acquir juli ssri partial agonist mdd merck atyp schizophrenia gx approv assum atyp antipsychot via gedeon richtertot central nervou strong franchis estimate guanyl cyclas agonist ibs-c cic acquir juli short-term treatment od dueoden ulcer acquir aptali mild/moder ulcer proctitit acquir aptali acquir octob exocrin pancreat insuffici due cf acquir aptali acquir furiex viokac pylera rectiv aquadek scandishak salofalk ultresatot strong gi franchis addit est/aptali furiex cowen
compani data cowen compani
lo loestrin gener introduc late decemb women atelvia crinon diafert levosert generess fe metronidazol fibristaltot women market leader excel track record space valsartin comobo pipelin hypertens specif beta blocker via jnjtotal small presenc inject broad-spectrum cephalosporin cap novel cephalosporin/beta lact us rights/azn rowavycaz infecti establish sale forc pipelin product bimatoprost eyelash growth purchas via kythera subment fat remov aczon topic antimicrobi formul acn tazorac medic dermatology/skin dermatolog estimate aczon major driver salin silicon addit product develop juvederm line success revenuearmour dermal cowen
compani data cowen compani
pipelin product rhofad esmya relamorelin ubrogep oral cgrp acut treatment migrain roll-out underway tavilermid mucin secret analog dri eye would complimentari lifitegrast/restasi rapastinel nmda receptor antagonist treatment-resist depress phase due abicipar longer-dur anti-vegf potenti profil file model assum modest pipelin success cowen
valuat methodolog primarili base current year forward price-to-earnings multipl
also consid total return/p ratio market cap/fre cash flow metric
failur pipelin product intellectu properti challeng econom sensit
price pressur and/or weaken consum demand develop market econom
and/or polit uncertainti emerg market chang tax law outlook
dividend fluctuat foreign exchang rate
risk includ heavi depend humira sale ep success pipelin
product notabl hepat portfolio success independ compani
